14 research outputs found
Meta-analysis: combination endoscopic and drug therapy to prevent variceal rebleeding in cirrhosis
Second-Line Rescue Therapy With Moxifloxacin After Failure of Treatment to Eradicate Helicobacter pylori Infection
565 Optimized Triple and Concomitant Therapy for Helicobacter pylori Eradication: The OPTRICON Study
Su1149 Two-Week, High-Dose Proton Pump Inhibitor, Moxifloxacin Triple H. pylori Therapy After Failure of Standard Triple or Non-Bismuth Quadruple Treatments
Su1129 H. pylori Second-Line Rescue Therapy With Levofloxacin and Bismuth After Failure of Standard Triple or Non-Bismuth Quadruple Treatment
Predictive factors of response to corticosteroid therapy in acute severe autoinmune hepatitis: a national multicentric study
Adverse Event Profile During the Treatment of Helicobacter pylori: A Real-World Experience of 22,000 Patients From the European Registry on H. pylori Management (Hp-EuReg)
INTRODUCTION: The safety of Helicobacter pylori eradication treatments and to what extent adverse events (AEs) influence therapeutic compliance in clinical practice are hardly known. Our aim was to assess the frequency, type, intensity, and duration of AEs, and their impact on compliance, for the most frequently used treatments in the "European Registry on Helicobacter pylori management.
Adverse Event Profile During the Treatment of Helicobacter pylori: A Real-World Experience of 22,000 Patients From the European Registry on H. pylori Management (Hp-EuReg)
INTRODUCTION: The safety of Helicobacter pylori eradication treatments and to what extent adverse events (AEs) influence therapeutic compliance in clinical practice are hardly known. Our aim was to assess the frequency, type, intensity, and duration of AEs, and their impact on compliance, for the most frequently used treatments in the "European Registry on Helicobacter pylori management.